Administration of aerolized drugs to patients diagnosed with COVID-19 leads to the risk of transmission of patient-generated infectiousaerosols to healthcare providers.While the COVID-19 pandemic is ongoing, in order to provide the best treatment for patients and atthe same time to protect healthcare providers at the highest level, it is necessary to increase access to information and pay maximumattention to preventive measures.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Administration of aerolized drugs to patients diagnosed with COVID-19 leads to the risk of transmission of patient-generated infectiousaerosols to healthcare providers.While the COVID-19 pandemic is ongoing, in order to provide the best treatment for patients and atthe same time to protect healthcare providers at the highest level, it is necessary to increase access to information and pay maximumattention to preventive measures.
📊
Temel Bulgular & Veri:Administration of aerolized drugs to patients diagnosed with COVID-19 leads to the risk of transmission of patient-generated infectiousaerosols to healthcare providers.While the COVID-19 pandemic is ongoing, in order to provide the best treatment for patients and atthe same time to protect healthcare providers at the highest level, it is necessary to increase access to information and pay maximumattention to preventive measures.
💡
Sonuç & Katkı:Administration of aerolized drugs to patients diagnosed with COVID-19 leads to the risk of transmission of patient-generated infectiousaerosols to healthcare providers.While the COVID-19 pandemic is ongoing, in order to provide the best treatment for patients and atthe same time to protect healthcare providers at the highest level, it is necessary to increase access to information and pay maximumattention to preventive measures.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Özet
Administration of aerolized drugs to patients diagnosed with COVID-19 leads to the risk of transmission of patient-generated infectiousaerosols to healthcare providers.While the COVID-19 pandemic is ongoing, in order to provide the best treatment for patients and atthe same time to protect healthcare providers at the highest level, it is necessary to increase access to information and pay maximumattention to preventive measures.
🔖
Bu Makaleye Atıf Yap
TOPEL, M., AKSU, K. (2020). Aerosol Medication Use in COVID-19 Pandemic. Astım Allerji İmmünoloji, Cilt: 18 - Sayı: 2, 110–112. https://ajindex.com/articles/351224
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. 2. https://www.who.int/news-room/q-a-detail/q-a-coronaviruses. (Accessed April 3, 2020.
Respiratory Therapy Group, Respiratory Medicine Branch, Chinese Medical Association. Expert consensus on protective measures related to respiratory therapy in patients with severe and critical coronavirus infection. Chinese Journal of Tuberculosis and Respiratory Diseases, 2020,17(00):E020 -E020. DOI: 10.3760 / cma.j.issn.1001-0939.2020.0020 4. www.ginasthma.org. (Accessed April 23, 2020.
Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: A systematic review. PLoS One 2012;7(4):e35797
Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer designs: Constant-output, breath-enhanced, and dosimetric. Respir Care 2004;49(2):174-9
Ari A. Practical strategies for a safe and effective delivery of aerosolizedmedications to patients with COVID-19. Respiratory Medicine 2020;167:105987
McGrath J, O’Toole C, GB, Joyce M, Byrne M, MacLoughlin R. Investigation of fugitive aerosols released into the environment during high-flow therapy. Pharmaceutics 2019;11:254
Wittgen BP, Kunst PW, Perkins WR, Lee JK, Postmus PE. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med 2006;19(3):385- 391
Ari A, Fink JB, Pilbeam S. Secondhand aerosol exposure during mechanical ventilation with and without expiratory filters: An in-vitro study. Ind J Resp Care 2016; 5(1): 677-82
Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: Low risk of bio-aerosol dispersion. Eur Respir J 2020;55(5):2000892
Hess DR. Medicated Aerosol Delivery Devices. In: Volsko TA, Chatburn RL, El-Khatib MF (eds). Equipment for Respiratory Care. Burlington, Massachusetts: Jones & Bartlett Learning; 2014:527-552
Hess DR. Humidity and aerosol therapy. In: Hess DR, MacIntyre NR, Galvin WF, Mishoe SC. (eds). Respiratory Care Principles and Practice, 4th ed. Burlington: Jones and Bartlett Learning, 2020: 321-65